Published: 2022-03-04


Using Genomics to Improve Pigmented Lesion Management & Health Outcomes

Clay Cockerell, Roger Ceilley, Mark Lebwohl, Darrell Rigel

Page 87-89

In-Depth Reviews

Original Research

Research Letters

Weekly Isotretinoin Therapy (WIT) Study: A Potential Alternative for the Treatment of Moderate Acne Vulgaris

Samantha Karlin, Alexandra Ritter, Courtney Linkous, Katherine Wehlage, Lara Wine Lee

Page 132-134


Brief Articles

Successful Dupilumab Treatment of Atopic Dermatitis in a Liver Transplant Patient

Amanda Krenitsky, Sairekha Ravichandran, Joel Cohen, Jonathan Braue, Lilia Correa-Selm

Page 135-137

Wells Syndrome with Sustained Response to Omalizumab

Kezia Surjanto, Gage Rensch, Garrett Vick, Andrea Murina

Page 138-142

Case Report and Review of Eccrine Porocarcinoma in Skin of Color

Sadhana Sruveera Sathi, Elizabeth M. Dugan, Maral Skelsey

Page 143-148

SARS-Cov-2 Infection Uncovering Latent Mycobacterium Leprae Infection

Christopher Mancuso, DO, MHS, Paloma Reiter, DO, Regina Zambrano, DO, Ritu Saini, MD, Suzanne Sirota-Rozenberg, DO

Page 157-161

A Diagnostic Challenge: Desmoplastic Melanoma

Katie O'Connell, Ryan Svoboda, Bryan Anderson, Klaus Helm, Kimberly Ken

Page 162-165

COVID Concepts

Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35)

Sophie Guenin, Emily Elbogen , Mindy Kresch , Mark Lebwohl

Page 166-169

Poster Presenations From Winter Clinical 2022 and FC PANP 2021: Psoriasis

Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials

Richard Langley, Diamant Thaci, Andrew Blauvelt, Tsen-Fang Tsai, Megan Miller, Jenny Yu, Yaung-Kaung Shen, Yin You, Ya-Wen Yang, Kim Papp, Luis Puig, Peter Foley

Page s1

Guselkumab (GUS) in Psoriasis Patients With a History of Malignancy: 5-Year Safety From VOYAGE (VOY)1&2

Andrew Blauvelt, Diamant Thaci, Kim Papp, Vincent Ho, Kamran Ghoreschi, Byung Soo Kim, Megan Miller, Yaung-Kaung Shen, Yin You, Jenny Yu, Ya-Wen Yang, Jeffrey Crowley, Peter Foley

Page s2

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials

Richard Warren , April Armstrong , Melinda Gooderham, Bruce Strober , Diamant Thaci, Shinichi Imafuku, Howard Sofen, Lynda Spelman, Neil Korman, Min Zheng, Elizabeth Colston, John Throup , Sundeep Kundu, Renata Kisa, Subhashis Banerjee, Andrew Blauvelt

Page s4

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Long-Term Extension Trial of a Novel Therapeutic Aryl Hydrocarbon Receptor Modulating Agent

Bruce Strober , Linda Stein Gold, Robert Bissonnette, April Armstrong , Andrew Blauvelt, Leon Kircik, Philip Brown, Anna Tallman, Mark Lebwohl

Page s5

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials

Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik

Page s6

Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3 Trials

Leon Kircik, Linda Stein Gold, James Del Rosso, Seemal Desai, Brad Glick, Howard Sofen, Anna Tallman, David Rubenstein, Janine Fournier, Philip Brown

Page s7

Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial

Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman

Page s8

Immunogenicity of Guselkumab (GUS) Among Psoriasis Patients in VOYAGE (VOY) 1&2 Studies

Kristian Reich , April Armstrong , Yaowei Zhu, Megan Miller, Yin You, Yaung-Kaung Shen, Ya-Wen Yang, Peter Foley, Christopher Griffiths, Bruce Strober

Page s11

Short Communications

Surprise Medical Billing Reform: Considerations for Dermatology

Yuangao Liu, Natalie Skopicki, Harrison Nguyen, Travis Blalock

Page 177-179

Acne & Rosacea

Treating Acne in Obese and Morbidly Obese Patients With Tazarotene 0.045% Lotion: Post Hoc Analysis of Pooled Phase 3 Data

Jonette Keri, Leon Kircik, Lawrence Green, Glynis Ablon, William Werschler, Emil Tanghetti, Zoe Draelos, Eric Guenin

Page s12

A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin  

James Del Rosso, Jeffrey Sugarman , Michael Gold, Krysten Arekapdui, Lawrence Green

Page s16

Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug

James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti

Page s17

Tazarotene 0.045% Lotion for Females With Acne: Analysis of Two Different Adult Age Groups

Neil Sadick, Fran Cook-Bolden, Kenneth Beer, Zoe Draelos, Leon Kircik, Emil Tanghetti, Eric Guenin

Page s18

Skin Cancer

Patient-Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis in Real-world Settings: PROAK Study Protocol

Brian Berman, April Armstrong , Mark Lebwohl, Ayman Grada, Neal Bhatia, Vishal Patel, Darrell Rigel, James Del Rosso, Todd Schlesinger, Leon Kircik, Raidah Salem, Ismail Kasujee

Page s19

Tirbanibulin Ointment Eradicates HPV-57 (+) Periungual Squamous Cell Carcinoma

Angela Moore, Stephen Moore, Qin He, Peter Rady, Ayman Grada, Stephen Tyring

Page s20

Complete clearance of actinic keratosis with tirbanibulin ointment 1% is not correlated with the severity of local skin reactions

Brian Berman, Todd Schlesinger, Neal Bhatia, Ayman Grada, Laura Padulles, Francisco Hernandez, david Cutler, Mark Lebwohl

Page s25

Impact of prior treatment in the efficacy and tolerability of tirbanibulin ointment 1% for actinic keratosis: pooled results from two Phase 3 studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Laura Padulles, Francisco Hernandez, David Cutler, Mark Lebwohl

Page s26

SKINmages: Clinical Images in Dermatology

Auricular Distortion Following Cryotherapy

Jason Bard, Heather Kornmehl , Joesph Wentzell

Page 180-182

An Uncommon Presentation Of Erosive Pustular Dermatosis: A Large, Crusted Plaque On The Scalp

James MacKenzie, Miriam Sagher, Ethan Sagher, Ben Friedman, Jesse Veenstra

Page 183-185

Atopic Dermatitis

Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Lawrence Eichenfeld, Eric Simpson, Kim Papp, Jacek Szepietowski, Leon Kircik, Darryl Toth, Seth Forman, Michael Kuligowski, May Venturanza, Haobo Ren, Amy Paller

Page s28

Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric Simpson

Page s29


Therapeutic Recommendations for the Treatment of Toenail Onychomycosis in the US

Shari Lipner, Warren Joseph , Tracey Vlahovic, Richard Scher, Phoebe Rich, Mahmoud Ghannoum, Ralph Daniel, Boni Elewski

Page s31